Protective effects of hydroxysafflower yellow A on pulmonary fibrosis in mice

doi:10.12047/j.cjap.6335.2022.103

Abstract

Abstract: Objective: To investigate the effect of hydroxysafflower yellow A (HSYA) on pulmonary fibrosis induced by bleomycin in mice and transforming growth factor β 1(TGF-β1) /Smad signal transduction pathway regulation. Methods: The pulmonary fibrosis model was prepared by intranasal injection of bleomycin 50 μl (15 mg/kg). ICR mice were randomly divided into control group, model group, HSYA group(6 mg/kg) and dexamethasone (Dex) group(3 mg/kg), with 15 mice in each group. From the next day of modeling, HSYA and Dex groups were intraperitoneally injected with corresponding drugs, while the control group and model group were intraperitoneally injected with the same volume of normal saline, once a day, for 28 consecutive days. After 4 weeks, the mice were sacrificed and the lungs were collected. HE and Masson staining were used to observe the pathological damage of lung tissue; Immunohistochemistry, RT-qPCR and Western blot were used to detect the expressions of TGF-β1/Smad signaling pathway in lung tissues. Results: Compared with the control group, the model group showed severe alveolitis and pulmonary fibrosis. The mRNA and protein expressions of TGF-β1 and Smad3 in lung tissues were increased significantly (P＜0.01), while the mRNA and protein expressions of Smad7 were decreased significantly (P＜0.01). Compared with the model group, the degree of alveolitis and pulmonary fibrosis in the HSYA and Dex groups was reduced significantly. The mRNA and protein expressions of TGF-β1 and Smad3 in lung tissues of HSYA and Dex groups were decreased significantly (P＜0.01), while the mRNA and protein expressions of Smad7 were increased significantly(P＜0.01). Conclusion: HSYA can alleviate the pathogenesis of pulmonary fibrosis, and its mechanism may be related to the regulation of TGF-β1/Smad signaling pathway.

Key words: hydroxysafflor yellow A, pulmonary fibrosis, TGF-β1/Smad, mice

CLC Number:

R285.5

LUAN Zhi-hua, WEI Yan-ming, CHANG Yin-xia. Protective effects of hydroxysafflower yellow A on pulmonary fibrosis in mice[J]. CJAP, 2022, 38(5): 555-558.

References

[1] Dong ZX, Lu X, Yang YN, et al. IL-27 alleviates the bleomycin-induced pulmonary fibrosis by regulating the Th17 cell differentiation[J]. BMC Pulm Med, 2015, 15: 13.
[2] Huang TT, Lai HC, Ko YF, et al. Hirsutella sinensis mycelium attenuates bleomycin-induced pulmonary inflammation and fibrosis in vivo[J]. Sci Rep, 2015, 5: 15282.
[3] Zheng M, Guo XJ, Pan RY, et al. Hydroxysafflor yellow A alleviates ovalbumin-induced asthma in a guinea pig model by attenuateing the expression of inflammatory cytokines and signal transduction[J]. Front Pharmacol, 2019, 10: 328.
[4] Song LJ, Zhu Y, Jin M, et al. Hydroxysafflor yellow a inhibits lipopolysaccharide-induced inflammatory signal transduction in human alveolar epithelial A549 cells[J]. Fitoterapia, 2013, 84: 107-114.
[5] Jin M, Sun CY, Zang BX. Hydroxysafflor yellow A attenuate lipopolysaccharide-induced endothelium inflammatory injury[J]. Chin J Integr Med, 2016, 22(1): 36-41.
[6] Sun L, Yang L, Xu YW, et al. Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: inhibition of protein oxidation/nitration,12/15-lipoxygenase and blood-brain barrier disruption[J]. Brain Res, 2012, 1473: 227-235.
[7] Yang FF, Li JM, Zhu JH, et al. Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice[J]. Eur J Pharmacol, 2015, 754:105-114.
[8] Hu HH, Chen DQ, Wang YN,et al. New insights into TGF-β/Smad signaling in tissue fibrosis[J]. Chem Biol Interact, 2018, 292: 76-83.
[9] 栾智华, 魏砚明, 刘必旺, 等.鼻腔滴注博莱霉素诱导ICR小鼠肺纤维化模型的建立[J]. 山西中医学院学报, 2017, 8(2): 18-21.
[10] Wang D, Yan ZB, Bu LL, et al. Protective effect of peptide DR8 on bleomycin-induced pulmonary fibrosis by regulating the TGF-β/MAPK signaling pathway and oxidative stress[J]. Toxicol Appl Pharmcol, 2019, 382: 114703.
[11] Mora AL, Rojas M, Pardo A, et al. Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease[J]. Nat Rev Drug Discov, 2017, 16: 775-772.
[12] Wang Y, Zhang CH, Peng WJ, et al. Hydroxysafflor yellow A exerts antioxidant effects in a rat model of traumatic brain injury[J]. Mol Med Rep, 2016, 14(4): 3690-3696.
[13] Sun Y, Xu DP, Qin Z, et al.Protective cerebrovascular effects of hydroxysafflor yellow A (HSYA) on ischemic stroke[J]. Eur J Pharmacol, 2018, 818: 604-609.
[14] Jin M, Wu Y, Wang L, et al. Hydroxysafflor yellow A attenuates bleomycin-induced pulmonary fibrosis in mice[J]. Phytother Res, 2016, 30(4): 577-587.
[15] Li NN, Feng FF, Wu K, et al. Inhibitory effects of astragaloside IV on silica-induced pulmonary fibrosis via inactivating TGF-β1/Smad3 signaling[J]. Biomed Pharmacother, 2019, 119: 109387.
[16] Han B, Lv ZJ, Zhang XY, et al. Deltamethrin induces liver fibrosis in quails via activation of the TGF-β1/Smad signaling pathway[J]. Environ Pollut, 2020, 259: 113870.
[17] Du N, Xu ZP, Gao MY, et al. Combination of ginsenoside Rg1 and astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy[J]. Drug Des Devel Ther, 2018, 12: 3517-3524.
[18] Pan RY, Zhang YD, Zang BX, et al. Hydroxysafflor yellow A inhibits TGF-β1-induced activation of human fetal lung fibroblasts in vitro[J]. J Pharm Pharmacol, 2016, 68(10): 1320-1330.
[19] 丁茂鹏, 韦凌霞, 王志旺, 等. 鳖甲育肝颗粒对复合因素所致肝纤维化大鼠 TGF-β1/Smads 通路的影响[J]. 中国应用生理学杂志, 2021, 37(5): 463-467.
[20] 李倩, 闫曙光, 惠毅, 等. 柔木丹改善小鼠肝纤维化的TGF-β1 /Smad4 信号通路机制[J]. 中国应用生理学杂志, 2020, 36(6): 576-581.